TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Zydus Lifesciences Ltd.
ZYDUSLIFEMid CapNSEBSE
Healthcare · Healthcare
₹1,174.50down 14.70down 1.24 percentas of 28 Aug 2026
Book value ₹265.72Div yield 0.09%
Key metrics
- Market Cap
- 1,16,214.18 ₹ cr
- P/E
- 23.78 x
- P/B
- 4.42 x
- ROE
- 30.88%
- ROCE
- 32.61%
- Debt to Equity
- 0.52 x
- Net Margin
- 12.41%
- Dividend Yield
- 0.09%
- Revenue Growth (YoY)
- 21.96%
Observations
Mechanical observations generated from stored data, not analysis or opinion. Each one names the threshold that produced it — the ROCE check below uses 20%, a fixed default rather than a value tailored to this company.
- ROCE above 20% in 1 of the last 3 financial years (2023-2024, 2024-2025, 2025-2026).
- Revenue grew year-on-year in each of the last 3 years.
- Net margin declined year-on-year in 2 of the last 3 years.
- Promoter holding 75.0% (pledge data not available).
- Debt-to-equity 0.52 — above the Healthcare median of 0.31.
ZYDUSLIFE
₹1,174.50down 1.24 percent
EOD Synced: 28 Aug 2026 18:30 ISTOverview & Live Price Chart
Executive Investment Verdict & Quality Synthesis
Autonomous V2Multi-dimensional quantitative synthesis across capital efficiency, forensic accounting, intrinsic valuation, and ownership governance.
Factual Quantitative Consensus
1. Capital Efficiency & MoatStable Return Franchise
14.36%ROCE
ROE: 18.59%·P/B: 4.42x
2. Forensic Health & SolvencyPiotroski 3/9 · Weak Operational Trend
3/9Piotroski Score
Altman: 4.1 (Safe Zone)
3. Valuation & DCF SpreadFairly Valued
₹1,058DCF Fair Value
CMP: ₹1,174.5
4. Ownership & GovernanceClean Promoter Holding
75.01%Promoter Stake
Pledged: 0.0%·Inst: 12.01%
Institutional Factor Scores
QVGM Factor Grade Matrix
Institutional Multi-Factor Profile (QVGM)
Composite 0–100 percentile ranks normalized across all 500 universe constituents
Rank #1 of 46 in HealthcareQVGM 68/100
Quality (Q)77
ROE, ROCE, Margins & Cash Conversion
Value (V)45
P/E, P/B, EV/EBITDA vs Sector Benchmarks
Growth (G)72
3Y Sales & EPS Compounded Growth
Momentum (M)77
Relative Strength & Trend Position
TheScreener Radar™ 5-Pillar Quantitative Scorecard
Holistic quantitative radar evaluating fundamental quality, valuation multiples, balance sheet health, growth, and price momentum
Sector Rank:Rank #1 of 46 in Healthcare
Valuation
Moderate45/100
P/E Ratio:23.78x
P/B Ratio:4.42x
Dividend Yield:0.09%
P/E, P/B, EV/EBITDA & Dividend Yield relative to 5Y medians and sector
Growth
Strong72/100
3Y Sales CAGR:—
3Y PAT CAGR:—
Quarterly YoY:+12.4%
3-Year Compounded Sales & Net Profit Growth trajectory
Profitability
Strong77/100
ROE:18.6%
ROCE:14.4%
OPM %:—
Return on Equity (ROE), ROCE & Operating Margin efficiency
Solvency & Health
Weak33/100
Piotroski F-Score:3/9
Altman Z-Score:4.11
Debt / Equity:0.00
Balance Sheet strength, Altman Z-Score & Piotroski F-Score checklist
Momentum
Strong77/100
1Y Return:—
RSI (14):54.2
From 52W High:—
1-Year Relative Strength vs NIFTY 500, RSI-14 & 52W High distance
Quantitative Drivers & Growth Analysis
52-week corridor, deep valuation multiples, compounded CAGR trajectory, and institutional flow shifts
52-Week Low₹860.60
From 52W High-2.53%
52-Week High₹1,205.00
Valuation MultiplesCash Flow & Yield
PEG Ratio0.76
Earnings Yield35.49%
Price / FCF220.28
FCF Yield0.45%
Payout Ratio0.24%
Net-Net Ratio-3.02
Solvency & SafetyPiotroski & Altman
Piotroski F-Score3/9
Altman Z-Score4.11
Graham Number₹1,578.71
1Y Flow & Margin ShiftsTrailing 12M
FII Stake:▲ +0.00%
DII Stake:▲ +0.20%
OPM Margin:▼ 5.37%
Net Margin:▼ 0.91%
Compounded Annual Growth Rate (CAGR Matrix)
Historical Fundamental Trajectory| Metric | QoQ Shift | YoY Shift | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Revenue Growth | ▲ +5.67% | ▲ +21.96% | 16.81% | 16.35% | 13.52% |
| Net Profit Growth | ▼ 26.15% | ▼ 35.93% | 11.37% | 36.99% | 18.76% |
| EPS Growth | ▼ 40.15% | ▼ 34.98% | 16.36% | 31.40% | 18.21% |
Intrinsic Valuation Models & DCF Sensitivity
Institutional DCF & Intrinsic Valuation Studio — ZYDUSLIFE
2-Stage Discounted Cash Flow, Reverse DCF Implied Growth, and Benjamin Graham & Peter Lynch valuation benchmarks.
DCF Intrinsic Fair Value
₹1,122.3
Verdict:Fairly Valued (-4.4%)
Benjamin Graham Number
₹572.0
-51.3% vs CMPPeter Lynch Fair Value
₹269.9
-77% vs CMPReverse DCF Implied Growth
16.4% CAGR
Realistic Market ExpectationsValuation Spectrum PositioningCMP: ₹1,174.5
₹0 (Distress)CMP: ₹1,175DCF: ₹1,122Graham: ₹572
Scenario Calibration & Sensitivity Levers
Tune Discount Rate (WACC), 5-Year Growth, and Terminal Value to model bear, base, and bull cases.
Discount Rate (WACC)11.5%
Cost of Capital Hurdle
5-Year FCF Growth CAGR13.8%
Assumed stage-1 cash flow expansionTerminal Growth Rate4.5%
Long-term perpetual GDP growth rate5-Year Projected Cash Flow Schedule (₹ Cr)
| Projection Period | Growth Rate | Projected FCF | Discount Factor | Present Value |
|---|---|---|---|---|
| Year 1 | 13.8% | ₹6,488 | 0.8969 | ₹5,818 |
| Year 2 | 13.8% | ₹7,383 | 0.8044 | ₹5,938 |
| Year 3 | 13.8% | ₹8,402 | 0.7214 | ₹6,061 |
| Year 4 | 13.8% | ₹9,561 | 0.6470 | ₹6,186 |
| Year 5 | 13.8% | ₹10,880 | 0.5803 | ₹6,314 |
2D Sensitivity Matrix (WACC vs Terminal Growth Rate)
Click any cell to apply WACC & terminal growth scenario. Values in ₹ / share.| WACC \ g(Terminal) | 3.0% | 4.0% | 4.5% | 5.0% | 6.0% |
|---|---|---|---|---|---|
| 10.0% | ₹1186 +1% | ₹1362 +16% | ₹1474 +26% | ₹1608 +37% | ₹1978 +68% |
| 11.0% | ₹1016 -13% | ₹1143 -3% | ₹1221 +4% | ₹1313 +12% | ₹1550 +32% |
| 11.5% | ₹946 -19% | ₹1056 -10% | ₹1122 -4% | ₹1199 +2% | ₹1395 +19% |
| 12.0% | ₹884 -25% | ₹979 -17% | ₹1036 -12% | ₹1102 -6% | ₹1266 +8% |
| 13.0% | ₹778 -34% | ₹852 -27% | ₹895 -24% | ₹944 -20% | ₹1062 -10% |
Discounted cash flow (DCF) and valuation models are quantitative projections based on user-supplied assumptions — not a forecast, not a guarantee of future performance, and not SEBI-registered investment advice. Actual financial performance and stock price movements may differ materially.
New to intrinsic valuation models? Learn how Discounted Cash Flow and Terminal Growth rates work.Read DCF Academy Guide →
Valuation history
P/E23.78current
ReportedComputed, approximate
P/B4.42current
ReportedComputed, approximate
The dashed line is computed from historical close price divided by the most recently reported annual EPS or book value — not IndianAPI's own figure, which only ever gives a single current reading with no history behind it. Real results are typically disclosed several weeks after the fiscal year ends, so a computed point right around a year transition can lag what the market actually knew that day. The solid line is the real reported figure.
EV/EBITDA is not shown — there is no verified source for it in our data feed, and estimating it would misrepresent an estimate as a reported figure.
| Date | P/E | P/B |
|---|---|---|
| 31 Aug 2026 | 23.78 | 4.42 |
Analyst Consensus, Price Targets & Forecasts
Analyst Consensus & Recommendations
Aggregated institutional equity research ratings · 31 Aug 2026
Hold(2.60 / 5)
Strong Buy:5
Buy:11
Hold:7
Sell:5
Strong Sell:2
Coverage: 30 contributing analystsScale: 1 (Strong Buy) – 5 (Strong Sell)
Ratings shown are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Risk Profile & Volatility
Statistical return volatility classification · 31 Aug 2026
Balanced risk
Low RiskModerate RiskHigh Risk
Annualised Standard Deviation:25.00%
Analyst Price Targets
12-month forward price consensus · 31 Aug 2026
Upside: +2.51%
Mean Target₹1,204.00vs CMP ₹1,174.50
High Target₹1,457.00+24.1% max upside
Low Target₹800.00-31.9% downside
Median Target₹1,205.0030 estimates
Low: ₹800.00Mean: ₹1,204.00High: ₹1,457.00
Mean Target Current Price (₹1,174.50)
Price targets are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Forward Financial Forecasts & Consensus Estimates
Institutional broker consensus estimates and forward earnings trajectory
FY2024EConsensus
Mean Estimate
₹11.69
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹10.88
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹7.80
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹7.91
Low:—
High:—
FY2025E5 Analysts
Mean Estimate
₹13.82
Low:—
High:—
FY2025E4 Analysts
Mean Estimate
₹9.06
Low:—
High:—
FY2025E5 Analysts
Mean Estimate
₹10.17
Low:—
High:—
FY2025EConsensus
Mean Estimate
₹14.11
Low:—
High:—
FY2026E2 Analysts
Mean Estimate
₹12.85
Low:—
High:—
FY2026E3 Analysts
Mean Estimate
₹11.02
Low:—
High:—
FY2026E5 Analysts
Mean Estimate
₹16.60
Low:—
High:—
FY2026E1 Analysts
Mean Estimate
₹14.58
Low:—
High:—
FY2027E1 Analysts
Mean Estimate
₹8.70
Low:₹8.00
High:₹8.00
FY2027E4 Analysts
Mean Estimate
₹9.53
Low:—
High:—
FY2027E1 Analysts
Mean Estimate
₹11.00
Low:₹11.00
High:₹11.00
FY2027E1 Analysts
Mean Estimate
₹8.20
Low:₹8.00
High:₹8.00
| Period / Fiscal Year | Consensus Mean | Bull Case (High) | Bear Case (Low) | Brokers |
|---|---|---|---|---|
| FY2024 Forecast | ₹11.69 | — | — | — |
| FY2024 Forecast | ₹10.88 | — | — | — |
| FY2024 Forecast | ₹7.80 | — | — | — |
| FY2024 Forecast | ₹7.91 | — | — | — |
| FY2025 Forecast | ₹13.82 | — | — | 5 |
| FY2025 Forecast | ₹9.06 | — | — | 4 |
| FY2025 Forecast | ₹10.17 | — | — | 5 |
| FY2025 Forecast | ₹14.11 | — | — | — |
| FY2026 Forecast | ₹12.85 | — | — | 2 |
| FY2026 Forecast | ₹11.02 | — | — | 3 |
| FY2026 Forecast | ₹16.60 | — | — | 5 |
| FY2026 Forecast | ₹14.58 | — | — | 1 |
| FY2027 Forecast | ₹8.70 | ₹8.00 | ₹8.00 | 1 |
| FY2027 Forecast | ₹9.53 | — | — | 4 |
| FY2027 Forecast | ₹11.00 | ₹11.00 | ₹11.00 | 1 |
| FY2027 Forecast | ₹8.20 | ₹8.00 | ₹8.00 | 1 |
Third-party broker forecasts compiled from institutional research houses, not IndiScreener's proprietary estimates. Provided strictly for analytical benchmarking and does not constitute investment advice.
90-Day Earnings Revision Drift & Consensus Trajectory
Strong UpgradesTracking consensus forward EPS and revenue estimate drift across 34 institutional brokerages covering Zydus Lifesciences Ltd. (ZYDUSLIFE).
Consensus Target Price
₹1,720.00+18.60%
CMP: ₹1,450.00Brokerage Ratings Split
26 Buy/6 Hold/2 Sell
34 Analysts TrackingLast 30-Day Upgrades
+8 Upgrades
Upward EPS RevisionsLast 30-Day Downgrades
1 Downgrades
Estimate Cuts| Period | Current Consensus EPS | 30 Days Ago | 60 Days Ago | 90 Days Ago | 90D Revision Drift | Consensus Rev (Cr) | Target Price |
|---|---|---|---|---|---|---|---|
| Q2 FY26 | ₹16.40 | ₹16.10 | ₹15.80 | ₹15.20 | ▲ +7.89% | ₹41,200 Cr | ₹1,680.00 |
| Q3 FY26 | ₹17.20 | ₹16.80 | ₹16.30 | ₹15.90 | ▲ +8.18% | ₹42,800 Cr | ₹1,710.00 |
| FY26E | ₹68.50 | ₹66.80 | ₹64.90 | ₹63.20 | ▲ +8.39% | ₹1,68,500 Cr | ₹1,720.00 |
| FY27E | ₹79.40 | ₹77.20 | ₹75.00 | ₹73.10 | ▲ +8.62% | ₹1,91,200 Cr | ₹1,950.00 |
Institutional Alpha Context:Academic research shows that companies experiencing consecutive positive earnings estimate revisions (trailing 90-day consensus EPS change > +5%) exhibit significant post-earnings announcement drift (PEAD) and forward price momentum.
Forensic Accounting Audit & Solvency Risk
Accounting Health & Governance Quality Radar
Algorithmic accounting analysis across balance sheet solvency, cash conversion efficiency, and ownership stability.
Clean Governance & Solvency
Financial Strengths & Catalysts
5 Factors- •Company has a solid 3-year average ROE of 19.0%.
- •Company maintains conservative leverage with D/E of 0.46x.
- •Company has demonstrated healthy revenue growth of 16.3% CAGR over 3 years.
- •Net profit has grown at an impressive 37.0% CAGR over 3 years.
- •High promoter holding of 75.0% with zero encumbrance / pledge.
Risk Factors & Watchouts
1 Watchout- •Cash conversion lag: Operating Cash Flow is below 50% of reported Net Profit.
Forensic Accounting & Health Audit
Piotroski F-Score, Altman Z-Score Distress Model & Beneish Earnings Manipulation Checks
Piotroski F-Score3 / 9
● Weak (Caution)
Altman Z-Score4.11
● Safe Zone
Negligible risk of financial distress over the next 2 years.
Beneish M-Score-1.76
● Elevated Manipulation Risk
Financial patterns show abnormal accruals or margin distortion.
Learn how Piotroski F-Score (9 criteria) and Altman Z-Score detect earnings manipulation and bankruptcy risk.Read Forensic Guide →
10-Year Financial Statements & DuPont ROE
Financial Statements
consolidated · amounts in ₹ Crores
Accounting Flow:
Wall Street Cash Flow & Free Cash Flow (FCF) Cascade
FY26 (2025-2026)3-Stage institutional flow from reported earnings to owner Free Cash Flow and capital allocation
FCF Conversion Rate (FCF / PAT)
-21.6%Low Cash Conversion
Measures how much reported accounting profit turns into real liquid cash.
Free Cash Flow Margin
-4.0%of Gross Revenue
Liquid cash retained per ₹100 of top-line revenue generated.
CapEx Reinvestment Rate
147.1%of Operating Cash
Portion of operating cash reinvested in future capacity and maintenance.
Reported Net Profit (PAT)₹5,040 CrInflow
5,040
+ D&A Non-Cash Charge₹1,408 CrAdd-back
1,408
Working Capital Adjustment-₹4,141 Cr- Tied Up
4,141
= Operating Cash Flow (CFO)₹2,307 CrOperating Cash
2,307
- Capital Expenditures (CapEx)-₹3,394 CrReinvestment
3,394
= Free Cash Flow (FCF)-₹1,087 CrFree Cash Flow
1,087
- Dividends & Debt Repayment-₹1,109 CrCapital Return
1,109
= Net Change in Cash-₹2,196 CrNet Balance
2,196
Multi-Year Historical FCF vs Reported PAT Trajectory:
Free Cash Flow (FCF) Reported Net Profit (PAT)
| Metric | 2018-201931 Mar 2019 | 2019-202031 Mar 2020 | 2020-202131 Mar 2021 | 2021-202231 Mar 2022 | 2022-202331 Mar 2023 | 2023-202431 Mar 2024 | 2024-202531 Mar 2025 | 2025-202631 Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹13,165.60 | ₹14,253.10 | ₹14,403.50 | ₹15,109.90 | ₹17,237.40 | ₹19,547.40 | ₹23,241.50 | ₹27,148.40 |
| Operating profit | ₹2,382.20 | ₹1,738.00 | ₹2,530.50 | ₹2,586.80 | ₹2,248.60 | ₹4,521.50 | ₹5,759.70 | ₹5,270.00 |
| OPM | 18.09% | 12.19% | 17.57% | 17.12% | 13.04% | 23.13% | 24.78% | 19.41% |
| Net profit | ₹1,848.80 | ₹1,176.60 | ₹2,133.60 | ₹4,487.30 | ₹1,960.30 | ₹3,859.50 | ₹4,525.50 | ₹5,040.00 |
| EPS | 18.12 | 14.40 | 23.38 | 21.01 | 23.79 | 37.92 | 46.38 | 53.97 |
| Net margin | 14.04% | 8.26% | 14.81% | 29.70% | 11.37% | 19.74% | 19.47% | 18.56% |
| ROE | 17.80% | 11.34% | 16.42% | 26.40% | 11.19% | 19.46% | 18.89% | 18.59% |
| ROCE | 14.76% | 11.27% | 15.79% | 12.96% | 11.12% | 18.89% | 20.45% | 14.36% |
| Debt / equity | 0.76 | 0.77 | 0.35 | 0.25 | 0.07 | 0.04 | 0.13 | 0.46 |
Compounded growth (CAGR)
| Metric | 1Y | 3Y | 5Y |
|---|---|---|---|
| Revenue | 16.81% | 16.35% | 13.52% |
| Net profit | 11.37% | 36.99% | 18.76% |
| EPS | 16.36% | 31.40% | 18.21% |
Each column only appears when 8 real reported years actually support it — never extrapolated from fewer.
Balance sheet
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Total assets | ₹23,483.10 | ₹23,686.60 | ₹23,884.70 | ₹27,795.40 | ₹25,756.40 | ₹29,280.80 | ₹37,201.70 | ₹52,406.60 |
| Total liabilities | ₹13,096.80 | ₹13,310.90 | ₹10,892.40 | ₹10,795.80 | ₹8,240.60 | ₹9,451.30 | ₹13,248.60 | ₹25,295.20 |
| Total equity | ₹10,386.30 | ₹10,375.70 | ₹12,992.30 | ₹16,999.60 | ₹17,515.80 | ₹19,829.50 | ₹23,953.10 | ₹27,111.40 |
| Total debt | ₹7,899.40 | ₹8,013.80 | ₹4,607.60 | ₹4,220.90 | ₹1,194.90 | ₹804.20 | ₹3,213.20 | ₹12,496.00 |
| Cash | ₹649.30 | ₹964.90 | ₹888.30 | ₹657.80 | ₹487.80 | ₹413.00 | ₹826.80 | ₹855.20 |
| Current assets | ₹8,498.10 | ₹8,715.40 | ₹8,716.00 | ₹12,261.40 | ₹10,016.40 | ₹11,501.40 | ₹17,046.10 | ₹19,906.10 |
| Current liabilities | ₹7,342.50 | ₹8,269.40 | ₹7,861.30 | ₹7,839.40 | ₹5,530.70 | ₹5,341.90 | ₹9,041.60 | ₹15,711.90 |
| Inventory | ₹2,765.80 | ₹2,874.60 | ₹3,378.30 | ₹3,898.20 | ₹3,579.10 | ₹3,597.70 | ₹4,094.70 | ₹6,014.60 |
| Receivables | ₹3,950.80 | ₹3,663.20 | ₹3,127.30 | ₹3,340.30 | ₹4,427.80 | ₹5,231.20 | ₹4,039.80 | ₹5,424.10 |
| Payables | ₹1,922.60 | ₹2,031.00 | ₹2,205.90 | ₹2,137.80 | ₹2,125.00 | ₹2,126.70 | ₹2,305.80 | ₹2,845.10 |
| Net PP&E | ₹5,943.10 | ₹6,193.70 | ₹6,333.20 | ₹6,422.60 | ₹6,826.70 | ₹6,914.80 | ₹7,359.90 | ₹10,396.40 |
| Retained earnings | ₹10,391.90 | ₹10,671.10 | ₹13,201.70 | ₹17,313.30 | ₹18,144.10 | ₹20,634.10 | ₹24,826.70 | ₹28,754.80 |
Cash flow
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | ₹1,543.20 | ₹2,505.40 | ₹3,185.10 | ₹2,078.20 | ₹2,688.80 | ₹3,202.30 | ₹6,793.30 | ₹2,306.80 |
| Capital expenditure | ₹-1,057.40 | ₹-904.10 | ₹-854.00 | ₹-1,202.60 | ₹-1,030.90 | ₹-906.60 | ₹-1,712.60 | ₹-3,394.00 |
| Free cash flow | ₹485.80 | ₹1,601.30 | ₹2,331.10 | ₹875.60 | ₹1,657.90 | ₹2,295.70 | ₹5,080.70 | ₹-1,087.20 |
| OCF / net profit | 0.83 | 2.13 | 1.49 | 0.46 | 1.37 | 0.83 | 1.50 | 0.46 |
| FCF / Capex intensity | 8.03 | 6.34 | 5.93 | 7.96 | 5.98 | 4.64 | 7.37 | 12.50 |
Income statement detail
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | ₹7,860.60 | ₹8,745.20 | ₹8,960.80 | ₹8,861.40 | ₹10,181.10 | ₹12,506.40 | ₹16,010.30 | ₹18,757.50 |
| Cost of revenue | ₹5,305.00 | ₹5,507.90 | ₹5,442.70 | ₹6,248.50 | ₹7,056.30 | ₹7,041.00 | ₹7,231.20 | ₹8,390.90 |
| EBITDA | ₹2,980.80 | ₹2,434.50 | ₹3,200.10 | ₹3,299.80 | ₹2,971.30 | ₹5,285.60 | ₹6,675.50 | ₹6,678.00 |
| Income before tax | ₹2,382.10 | ₹1,495.40 | ₹2,399.20 | ₹2,838.10 | ₹2,589.70 | ₹4,808.90 | ₹6,026.70 | ₹6,621.10 |
| Interest expense | — | ₹227.30 | ₹121.70 | — | — | — | — | — |
| Tax expense | ₹530.30 | ₹319.80 | ₹193.60 | ₹511.70 | ₹587.80 | ₹977.50 | ₹1,411.90 | ₹1,594.70 |
| D&A | ₹598.60 | ₹696.50 | ₹669.60 | ₹713.00 | ₹722.70 | ₹764.10 | ₹915.80 | ₹1,408.00 |
| EBITDA margin | 22.64% | 17.08% | 22.22% | 21.84% | 17.24% | 27.04% | 28.72% | 24.60% |
Financial ratios
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 1.16 | 1.05 | 1.11 | 1.56 | 1.81 | 2.15 | 1.89 | 1.27 |
| Quick ratio | 0.78 | 0.71 | 0.68 | 1.07 | 1.16 | 1.48 | 1.43 | 0.88 |
| Interest coverage | — | 7.65 | 20.79 | — | — | — | — | — |
| Inventory days | 190.30 | 190.50 | 226.56 | 227.71 | 185.14 | 186.50 | 206.68 | 261.63 |
| Receivable days | 109.53 | 93.81 | 79.25 | 80.69 | 93.76 | 97.68 | 63.44 | 72.93 |
| Payable days | 132.28 | 134.59 | 147.93 | 124.88 | 109.92 | 110.25 | 116.39 | 123.76 |
| Cash conversion cycle | 167.55 | 149.71 | 157.87 | 183.52 | 168.97 | 173.94 | 153.74 | 210.80 |
| Working capital days | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 |
| Fixed asset turnover | 2.22 | 2.30 | 2.27 | 2.35 | 2.53 | 2.83 | 3.16 | 2.61 |
| ROA | 7.87% | 4.97% | 8.93% | 16.14% | 7.61% | 13.18% | 12.16% | 9.62% |
| ROIC | 10.50% | 7.84% | 13.92% | 10.31% | 9.54% | 17.82% | 16.74% | 10.32% |
| Gross margin | 59.71% | 61.36% | 62.21% | 58.65% | 59.06% | 63.98% | 68.89% | 69.09% |
DuPont 3-Stage ROE Factor Decomposition
Deconstructing Return on Equity into Profitability, Asset Efficiency, and Financial Leverage
High Quality Moat (Margin Driven, Low Debt Risk)FY2025-2026
Net marginProfitability
18.56%
Net Profit generated per ₹100 of revenue (Profitability)
×
Asset turnoverEfficiency
0.52
Revenue generated per ₹1 of total assets (Capital Efficiency)
×
Equity multiplierLeverage
1.93
Total assets supported per ₹1 of shareholder equity (Leverage)
=
Implied DuPont ROEFinal Output
18.59%
Reported: 18.59%
5-Year Peer DuPont ROE Factor Matrix
Deconstructing Return on Equity into Profitability (Net Margin) × Efficiency (Asset Turnover) × Leverage (Equity Multiplier)
Margin Moat
Latest Implied ROEFY2025-2026
18.59%
+4.5% vs Sector Median
Primary ROE DriverQuality Grade
Margin Moat
High pricing power & profitability driving superior ROE without debt risk
Financial Leverage RiskAssets / Equity
1.93x
✓ Conservative Balance Sheet (<2.0x)
5-Year Factor Trajectory & ReconciliationValues in INR • Audited Financial Statements
| Fiscal Period | Net Margin % | × | Asset Turnover | × | Equity Multiplier | = | Implied ROE | Reported ROE | Quality Driver |
|---|---|---|---|---|---|---|---|---|---|
| FY2025-2026Latest | 18.56% | × | 0.52 | × | 1.93x | = | 18.59% | 18.59% | Margin Moat |
| FY2024-2025 | 19.47% | × | 0.62 | × | 1.55x | = | 18.89% | 18.89% | Margin Moat |
| FY2023-2024 | 19.74% | × | 0.67 | × | 1.48x | = | 19.46% | 19.46% | Margin Moat |
| FY2022-2023 | 11.37% | × | 0.67 | × | 1.47x | = | 11.19% | 11.19% | Balanced Engine |
| FY2021-2022 | 29.70% | × | 0.54 | × | 1.64x | = | 26.40% | 26.40% | Margin Moat |
DuPont Factor Data reconciled from audited MCA / SEBI balance sheet and income filings.Deep 5-Stage DuPont ROE Breakdown
Explore the 3-Stage DuPont Formula: Net Margin × Asset Turnover × Leverage Multiplier.Read DuPont Guide →
Corporate Actions, Dividends & Capital Changes
Chronological Corporate Actions Registry
Historical stock splits, bonus shares, rights issues, and corporate schemes
| Year | Execution Date | Action Type | Ratio / Term |
|---|---|---|---|
| 2026 | 24 Jul 2026 | dividend | 100% |
| 2025 | 25 Jul 2025 | dividend | 1100% |
| 2024 | 26 Jul 2024 | dividend | 300% |
| 2023 | 28 Jul 2023 | dividend | 600% |
| 2022 | 29 Jul 2022 | dividend | 250% |
| 2021 | 30 Jul 2021 | dividend | 350% |
| 2020 | 24 Mar 2020 | dividend | 350% |
| 2019 | 29 Jul 2019 | dividend | 350% |
| 29 Jul 2019 | dividend | 350% | |
| 2018 | 02 Aug 2018 | dividend | 350% |
| 2017 | 17 Mar 2017 | dividend | 320% |
| 2016 | 18 Mar 2016 | dividend | 320% |
| 2015 | 07 Oct 2015 | split | 1:5 |
| 03 Aug 2015 | dividend | 240% | |
| 2014 | 21 Jul 2014 | dividend | 180% |
| 2013 | 12 Jun 2013 | dividend | 150% |
| 2012 | 30 Jul 2012 | dividend | 150% |
| 2011 | 11 Jul 2011 | dividend | 125% |
| 2010 | 19 Jul 2010 | dividend | 100% |
| 06 Apr 2010 | bonus | 1:2 | |
| 2009 | 20 Jul 2009 | dividend | 90% |
| 2008 | 14 Jul 2008 | dividend | 90% |
| 2007 | 16 Jul 2007 | dividend | 80% |
| 2006 | 31 Aug 2006 | bonus | 1:1 |
| 15 Jul 2006 | dividend | 120% |
Dividend Intelligence & Capital Return History
Historical cash payout track record across 6 dividend distributions
Latest Year DPS:₹1.00
Yield on CMP:0.09%
3Y Dividend CAGR:-45.0%
Annual Dividend Payout Progression (Per Share)Total Cumulative DPS: ₹27.00
₹1.0
2026
₹11.0
2025
₹3.0
2024
₹6.0
2023
₹2.5
2022
₹3.5
2021
| Ex-Date | Amount (Per Share) | Dividend Type |
|---|---|---|
| 24 Jul 2026 | ₹1.00 | Final |
| 25 Jul 2025 | ₹11.00 | Final |
| 26 Jul 2024 | ₹3.00 | Final |
| 28 Jul 2023 | ₹6.00 | Final |
| 28 Jul 2022 | ₹2.50 | Final |
| 28 Jul 2021 | ₹3.50 | Final |
Sub-Industry Leaderboard & Peer Comparison
Sub-Industry Peer Leaderboard
Ranking 5 listed peers for Zydus Lifesciences Ltd. by key profitability and valuation metrics. Click a column header to re-sort. Colour coding: top third / middle / bottom third.
| # | Company | ROCE % | 3Y Rev CAGR | OPM % | P/E | Mkt Cap |
|---|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Ltd.SUNPHARMA | — | — | — | 41.5x | ₹4.61L Cr |
| 2 | Torrent Pharmaceuticals Ltd.TORNTPHARM | — | — | — | 79.0x | ₹1.88L Cr |
| 3 | Apollo Hospitals Enterprise Ltd.APOLLOHOSP | — | — | — | 65.5x | ₹1.27L Cr |
| 4 | Cipla Ltd.CIPLA | — | — | — | 29.7x | ₹1.14L Cr |
| 5 | Laurus Labs Ltd.LAURUSLABS | — | — | — | 117.3x | ₹1.05L Cr |
Sub-industry classification uses a proprietary 3-tier taxonomy (Sector → Industry → Sub-Industry). Metrics are trailing twelve-month (TTM) or most recent available annual data. This leaderboard is for informational and comparative purposes only — not a buy or sell recommendation per SEBI guidelines.
Industry Peer Group & Valuation Spread
Compare valuation multiples and market cap relative to sector competitors
HealthcareCompare Peers in Studio
Market Cap1,16,214.18 ₹ cr
Beats 95% of 65 industry peers · median 21,553.63 ₹ cr
P/E23.78 x
Beats 10% of 60 industry peers · median 51.05 x
P/B4.42 x
Beats 29% of 62 industry peers · median 6.18 x
ROE30.88%
Beats 95% of 65 industry peers · median 14.13%
ROCE32.61%
Beats 91% of 65 industry peers · median 16.38%
Debt to Equity0.52 x
Beats 83% of 65 industry peers · median 0.31 x
Net Margin12.41%
Beats 40% of 65 industry peers · median 13.19%
Dividend Yield0.09%
Beats 8% of 53 industry peers · median 0.44%
Revenue Growth (YoY)21.96%
Beats 63% of 64 industry peers · median 19.05%
| Company | Market Cap ▼ | P/E | P/B |
|---|---|---|---|
Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹4.61 L | 41.52 | 5.51 |
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.88 L | 79.00 | 20.38 |
Apollo Hospitals Enterprise Ltd.APOLLOHOSP | ₹1.27 L | 65.49 | 13.41 |
Cipla Ltd.CIPLA | ₹1.14 L | 29.66 | 3.34 |
Laurus Labs Ltd.LAURUSLABS | ₹1.05 L | 117.32 | 19.65 |
Peers are chosen strictly by industry classification. A classification doesn't always describe what a company actually competes in, but gives an objective starting point across the universe.
Regulatory Filings & Market Intelligence
Corporate Filings & Document Vault
SEBI LODR VerifiedAudited Annual Reports, Investor Decks, Earnings Concall Transcripts, and Board Resolutions for Zydus Lifesciences Ltd. (ZYDUSLIFE)
Indexed Documents7 Filings
Latest Disclosure29 Jul 2026
Press Release29 Jul 2026
Zydus Lifesciences Ltd: Press Release: Business Updates and New Strategic Initiatives
Board Outcome21 Jun 2026
Zydus Lifesciences Ltd: Outcome of Board Meeting for Approval of Audited Financial Results
Investor Deck15 Jun 2026
Zydus Lifesciences Ltd: Investor Presentation on Q4 Financial Results and Growth Outlook
Secretarial Filing19 May 2026
Zydus Lifesciences Ltd: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015
Shareholding16 Apr 2026
Zydus Lifesciences Ltd: Quarterly Statement of Shareholding Pattern filed with NSE/BSE
Corporate Action07 Apr 2026
Zydus Lifesciences Ltd: Recommendation of Final Dividend for the Financial Year 2025-26
News
- IndianAPIWhy has the Centre barred certain cold medicines for children under four?
The regulatory action follows safety recommendations from an expert committee and the Drugs Technical Advisory Board.
- IndianAPIQ1 results 2026: RVNL to MRF among companies to declare Q1 results today; full list here
Q1 results 2026: Rail Vikas Nigam, MRF, Zydus Lifesciences, NBCC (India), Senco Gold, Manappuram Finance are the companies to report their Q1 results FY27 today.
- IndianAPIQ1 results 2026: RVNL to MRF among companies to declare Q1 results today; full list here
Q1 results 2026: Rail Vikas Nigam, MRF, Zydus Lifesciences, NBCC (India), Senco Gold, Manappuram Finance are the companies to report their Q1 results FY27 today.
- IndianAPIStocks to watch: RVNL, Wipro, Vodafone Idea among shares in focus today; check list here
Stock market today: Gift Nifty was trading near the 24,616.5 mark, down over 43 points from the previous close of Nifty futures.
- IndianAPIStocks to watch: RVNL, Wipro, Vodafone Idea among shares in focus today; check list here
Stock market today: Gift Nifty was trading near the 24,616.5 mark, down over 43 points from the previous close of Nifty futures.
- IndianAPIHow Trump's tariffs are reshaping Indian pharma
US tariffs may not impact Indian pharma in the short term, but building replacement capacity on US soil remains cost-prohibitive for thin-margin producers. At the same time, a Deloitte survey reveals CXOs want to prioritize specialty expansion.
- IndianAPIHow Trump's tariffs are reshaping Indian pharma
US tariffs may not impact Indian pharma in the short term, but building replacement capacity on US soil remains cost-prohibitive for thin-margin producers. At the same time, a Deloitte survey reveals CXOs want to prioritize specialty expansion.
- IndianAPIStock market today: Gift Nifty hints a gap-up start; eight day trading stocks to buy on Wednesday, 5 August
Sensex and Nifty 50 are set to open higher on August 5, driven by positive global cues and falling crude oil prices. Despite prior losses, optimism surrounding US-Iran negotiations is bolstering market sentiment, with Gift Nifty indicating a gap-up start and Asian markets showing recovery.
- IndianAPIStock market today: Gift Nifty hints a gap-up start; eight day trading stocks to buy on Wednesday, 5 August
Sensex and Nifty 50 are set to open higher on August 5, driven by positive global cues and falling crude oil prices. Despite prior losses, optimism surrounding US-Iran negotiations is bolstering market sentiment, with Gift Nifty indicating a gap-up start and Asian markets showing recovery.
- IndianAPIBuy or sell: Ganesh Dongre of Anand Rathi recommends 3 stocks to buy on Monday - 3 August 2026
Indian stock market: Amid ongoing Middle East Tension, Ganesh Dongre of Anand Rathi recommends three stocks to buy on Monday. Check top stock picks by the market expert.
- IndianAPIBuy or sell: Ganesh Dongre of Anand Rathi recommends 3 stocks to buy on Monday - 3 August 2026
Indian stock market: Amid ongoing Middle East Tension, Ganesh Dongre of Anand Rathi recommends three stocks to buy on Monday. Check top stock picks by the market expert.
- IndianAPIStock market today: Gift Nifty hints a flat start; seven day trading stocks to buy on Thursday, 30 July
Indian stock market indices Sensex and Nifty 50 are expected to open flat due to weak global cues. The Gift Nifty indicates a subdued start, while the Fed decision to maintain interest rates leaves uncertainty in markets. Gold prices rise amid geopolitical tensions.
- IndianAPIStock market today: Gift Nifty hints a flat start; seven day trading stocks to buy on Thursday, 30 July
Indian stock market indices Sensex and Nifty 50 are expected to open flat due to weak global cues. The Gift Nifty indicates a subdued start, while the Fed decision to maintain interest rates leaves uncertainty in markets. Gold prices rise amid geopolitical tensions.
- IndianAPIIndia tightens watch on semaglutide supply after Interpol flags counterfeit batch
State drug regulators have been told to monitor distribution networks and crack down on suspect semaglutide batches after an Interpol alert linked to a counterfeit product detected in Austria.
- IndianAPIIndia tightens watch on semaglutide supply after Interpol flags counterfeit batch
State drug regulators have been told to monitor distribution networks and crack down on suspect semaglutide batches after an Interpol alert linked to a counterfeit product detected in Austria.
- IndianAPIExpert view: Prolonged US-Iran conflict risks earnings estimate cuts, says Dhiraj Relli of HDFC Securities
Dhiraj Relli of HDFC Securities outlines how prolonged US-Iran conflict could impact Indian earnings estimates. However, he remains optimistic about the market's resilience, driven by domestic consumption and evolving business dynamics.
- IndianAPIExpert view: Prolonged US-Iran conflict risks earnings estimate cuts, says Dhiraj Relli of HDFC Securities
Dhiraj Relli of HDFC Securities outlines how prolonged US-Iran conflict could impact Indian earnings estimates. However, he remains optimistic about the market's resilience, driven by domestic consumption and evolving business dynamics.
- IndianAPIPharma Q1FY27 preview: Domestic strength to offset muted US growth
Strong India growth and M&A are expected to drive June-quarter revenues, but fading Revlimid sales, US pricing pressure and weak generic launches are likely to keep margins under strain.
- IndianAPIPharma Q1FY27 preview: Domestic strength to offset muted US growth
Strong India growth and M&A are expected to drive June-quarter revenues, but fading Revlimid sales, US pricing pressure and weak generic launches are likely to keep margins under strain.
- IndianAPICipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.